

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/26210 A2

(51) International Patent Classification⁷: A61K 9/00

(21) International Application Number: PCT/US01/42298

(22) International Filing Date:
25 September 2001 (25.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/236,993 29 September 2000 (29.09.2000) US

(71) Applicant (for all designated States except US): GENEVA
PHARMACEUTICALS INC. [US/US]; 2655 West Mid-
way Boulevard, Broomfield, CO 80038 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CULLEN, Dan
[US/US]; 2385 Cessna Drive, Erie, CO 80516 (US). PEL-
LONI, Christopher, L. [US/US]; 2058 Maple Avenue,
Apt. AH1-12, Hatfield, PA 19440 (US).

(74) Agents: FURMAN, Diane, E. et al.; Novartis Pharma-
ceuticals Corporation, 564 Morris Avenue, Summit, NJ
07901-1027 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.


(54) Title: PROTON PUMP INHIBITOR FORMULATION

(57) Abstract: Pharmaceutical capsule dosage forms of benzimidazole proton pump inhibitors are prepared by enclosing one or several enteric coated compressed cores in a capsule shell. The inventive formulations are stable and have higher bioavailability of the active ingredient relative to pellet and granule containing formulations.

WO 02/26210 A2

Proton Pump Inhibitor FormulationBackground

Benzimidazole compounds of the formula (I)



wherein R^1 to R^5 are defined later herein, are known as gastric proton pump inhibitors and have utility in the treatment of gastric and duodenal ulcers, gastroesophageal reflux disease and other conditions associated with excess gastric acid secretion. Several of these compounds are commercially available and/or have been tested clinically, for example, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole and pantoprazole.

Although these compounds are reported to have a high degree of therapeutic utility, they are also reported to be highly acid labile. This has presented a problem to formulators of oral dosage forms, such as capsules, because the acid labile compounds react with both gastric acid in the stomach and with enteric coatings used to prevent the benzimidazole compound from coming into contact with gastric acid.

U.S. Patent No. 4,786,505 reports solving this problem by formulating the benzimidazole compound (omeprazole) and an alkaline-reacting compound into pellets and coating the pellets with an inert subcoating and then an enteric coating. The alkaline reacting compound presumably increases stability by maintaining the benzimidazole compound in an alkaline environment and the inert subcoating prevents contact between the benzimidazole compound and the enteric coating.

U.S. Patent No. 5,626,875 reports a stable formulation which does not contain an alkaline-reacting compound but which also utilizes an inert subcoat to prevent contact between the benzimidazole compound and the enteric coating. The formulation is prepared by coating spherical inert cores with a first layer of the benzimidazole compound, a non-

alkaline water soluble polymer and non-alkaline excipients, followed by a second layer of the non-alkaline water soluble polymer and non-alkaline excipients, followed by a third layer which is an enteric coating.


According to the present invention neither the alkaline reacting compound nor the subcoat are required if the enteric coating is applied to a compressed core containing the active ingredient. Generally, such compressed cores are distinguished from known pellet formulations by being significantly harder and denser and by having a significantly lower surface area to volume ratio due to the significantly reduced surface area for the same volume occupied. From one to six, preferably one to four, of such enteric-coated compressed cores are encapsulated in a capsule shell to provide a capsule dosage form which meets all of the stability and purity requirements necessary to be commercially marketed as a pharmaceutical product.

Surprisingly, the inventive approach to formulating benzimidazole compounds provides a stable formulation which has improved bioavailability relative to the commercially-available enteric coated pellet or granule containing formulations, such as the omeprazole product marketed as PRILOSEC or LOSEC capsules, the lansoprazole product marketed as PREVACID or the rabeprazole product marketed as ACIPHEX.

DETAILED DESCRIPTION

The present disclosure describes inventive capsule dosage forms for benzimidazole proton pump inhibitors. The inventive capsule dosage forms provide improved bioavailability compared with known pellet- or granule-based dosage forms as well as appropriate stability for a commercial pharmaceutical dosage form.

The inventive capsule dosage forms are delayed-release pharmaceutical capsule dosage forms which comprise one or several enteric-coated, compressed cores encapsulated by a capsule shell, wherein the enteric-coated compressed core consists essentially of a mixture of a pharmaceutically acceptable carrier and an pharmaceutically effective amount of a pharmaceutically active compound of the formula (I)



wherein R^1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R^2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxy carbonylmethyl or alkylsulfonyl, R^3 and R^5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R^4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, or a pharmaceutically acceptable salt thereof;

which mixture has been compressed at a pressure in the range from 350 to 1500 pounds into a compressed core and the compressed core is directly coated with an effective release-delaying amount of an enteric coating. Preferably, the compression pressure is in the range from 500 to 1200 pounds.

Generally, the capsule dosage form will contain 1 or several compressed cores. As a practical matter the upper limit is about 6 compressed cores per capsule. Although the capsule dosage form can contain from 1 up to about 6 compressed cores, it is preferable for the capsule dosage form to contain from 1 to 4 compressed cores, for example 1, 2, 3 or 4 compressed cores.

It is possible for the carrier to be essentially neutral meaning that it is not required for the carrier to function to keep an alkaline microenvironment within the compressed core. However, the carrier should not create an acidic microenvironment due to the acid lability of the benzimidazole compounds.

Essentially neutral carriers include fillers, surfactants, disintegrants, lubricants, binders and the like. Suitable fillers include lactose, sucrose, mannitol, dextrose, dextrates, sorbitol, dibasic calcium phosphate, microcrystalline cellulose, cellulose powder, starch, pregelatinized starch and the like. Suitable surfactants include polysorbates, sodium lauryl sulfate and polaxomers. Suitable disintegrants include croscopovidone, sodium starch glycolate

and croscarmellose sodium. Suitable lubricants include magnesium stearate, sodium stearyl fumarate and hydrogenated vegetable oil. Suitable binders include povidone, starch, dextrin and the like.

Generally, each compressed core has a volume in the range from about 13 to 1230 mm³ and a surface area to volume ratio of from 0.5 to 2.7 mm⁻¹, preferably 0.5 to 2.5 mm⁻¹, for example a volume in the range from about 25 mm³ to 450 mm³ or about 75 mm³ to 450 mm³ and a surface area in the range from about 50 mm² to 350 mm² or about 100 mm² to 350 mm² with a surface area to volume ratio of from about 0.5 to 2.5 mm⁻¹.

Generally, each compressed core will contain the same portion of the pharmaceutically active ingredient. Thus, if there are 4 compressed cores, each will contain 25% of the total dose, and, if there are 2 compressed cores, each will contain 50% of the total dose of active ingredient. However, variations are possible within the scope of the invention.

Normally, the benzimidazole compounds are provided in dosage forms containing from 10 to 50 mg of the active ingredient and each compressed core normally contains from 3 to 25 milligrams, for example 5 to 15 mg, of the pharmaceutically active compound. For example, omeprazole is marketed in 10, 20, 30 and 40 mg strengths and the 20 mg strength can comprise 4x5 mg compressed cores or 2x10 mg compressed cores and so on. As another example, lansoprazole is marketed in 15 and 30 mg strengths and the 30 mg strength can comprise 2x15 mg, 4x7.5 mg, 3x10mg or 6x5 mg compressed cores and the 15 mg strength can comprise 3x5 mg, 2x7.5 mg or 1x15 mg compressed cores.

Preferably, the compound of formula (I) is selected from the group consisting of omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole and pantoprazole; especially omeprazole or lansoprazole.

Enteric coatings suitable for application directly to the compressed core are well-known in the pharmaceutical arts. Generally, the enteric coating is a gastric resistant polymer such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and copolymers, methacrylic acid

polymers and copolymers. Copolymers of methacrylic acid and methacrylic acid methyl ester are especially useful as the enteric coating.

Although some discoloration may occur if an inert subcoating is absent, the subcoating is not necessary for stability purposes. Thus, capsule dosage forms wherein the enteric coating is applied directly (i.e. in the absence of a subcoating) to the compressed core are within the scope of the present invention.

The enteric coating is generally applied at a level which is effective to render the compressed core impermeable to gastric fluid.

There are four essential steps to preparing the inventive capsule dosage forms: mixing, compression, enteric coating and encapsulation.

The mixing step is carried out by known methods, preferably dry blending or wet granulation methods. Generally, the benzimidazole compound is dry blended with the carrier in a high or low sheer mixing apparatus, such as a vertical mixer, horizontal mixer, twinshell blender, double cone blender or a reciprocal blender, followed by de-agglomeration, roller compacted and milled to obtain a desirable particle size distribution. Alternatively, the mixing step is a wet granulation followed by drying, deagglomeration and milling. The milled material may be further blended with excipients, such as lubricants, to improve various properties.

The milled material is then compressed on a conventional tablet press, for example, a rotary tablet press, to yield a compressed core which is not friable and which has a hardness of about 3 Strong-Cobb units or greater.


The compressed core is then enteric coated by applying an effective amount of an enteric coating to render the tablet impermeable to gastric media. The coating operation is carried out in conventional or perforated coating pans, or may be carried out in a fluid bed apparatus.

The enteric coated compressed core is then filled into a capsule shell utilizing conventional encapsulation equipment with a tablet filling station. Such equipment is known in the art. A filler may be added to the capsule to eliminate rattling of the capsules in the

capsule shell. If desired, the filler may contain additional pharmaceutical active ingredients to prepare a capsule dosage form containing a delayed-release proton pump inhibitor and an immediate release additional pharmaceutical agent.

The inventive formulations have improved bioavailability relative to pellet and granule formulations. Thus, the present invention especially relates to an omeprazole dosage form which has improved bioavailability relative to the omeprazole formulation which is the subject of U.S. Food and Drug Administration approved New Drug Application 19810, and to a lansoprazole dosage form which has improved bioavailability relative to the lansoprazole formulation which is the subject of U.S. Food and Drug Administration approved New Drug Application 20406. It is believed, although not certain, and without being bound to any particular theory, that the inventive formulations have improved bioavailability relative to the commercial formulations which contain enteric coated granules or pellets because a portion of the granules or pellets in the commercial products release their contents in the stomach and the active ingredient is decomposed before it is absorbed into the bloodstream.

The present invention further relates to a method of inhibiting the secretion of gastric acid in a mammalian subject which comprises administering to the subject a delayed-release, pharmaceutical capsule dosage form, which comprises one or more enteric-coated, compressed cores encapsulated by a capsule shell, wherein the enteric-coated compressed core consists essentially of a core which is a mixture of a pharmaceutically acceptable carrier and an effective amount of a pharmaceutically active compound of the formula (I)




wherein R^1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R^2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R^3 and R^5 are the same or different and each is

hydrogen, alkyl, alkoxy or alkoxyalkoxy, R^4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4;

which mixture has been subjected to compression at a pressure in the range from 350 to 1500 pounds. The invention especially relates to a method wherein the bioavailability of the benzimidazole compound is enhanced relative to a pellet- or granule-containing reference formulation.

The present invention further relates to a process for preparing a enteric-coated, capsule dosage form containing a pharmaceutical effective amount of a compound of formula (I)



wherein R^1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R^2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxy carbonylmethyl or alkylsulfonyl, R^3 and R^5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R^4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4;

which consists essentially of the steps of

- (i) compressing a mixture of a compound of formula (I) and a pharmaceutically acceptable carrier at a pressure in the range from 350 to 1500 pounds to form a compressed core which has a surface area to volume ratio of from 0.5 to 2.5 mm^{-1} ;
- (ii) coating the compressed core with an effective release-delaying amount of an enteric coating to form an enteric-coated compressed core; and
- (iii) encapsulating from 1 to 4 enteric-coated compressed cores in a capsule shell to form a delayed-release capsule dosage form containing a pharmaceutically effective amount of a compound of formula (I).

Example 1

Omeprazole 20 mg capsules are prepared by the following procedure:

(1) The following ingredients are dry blended for 3 minutes in a 40 liter BOHLE blender:

omeprazole	1000g
anhydrous lactose	3695g
microcrystalline cellulose	600g
sodium lauryl sulfate	120g
croscarmellose sodium	224g

(2) After blending is complete, the blended composition is roller compacted in a FITZPATRICK IRL-520 CHILOSONATOR roller compactor at the following settings:

roll speed	10 rpm
roll pressure	1400 psi
mill speed	2000 rpm
mill screen	79
vertical feed screw	100 rpm
horizontal feed screw	20 rpm

(3) 60 grams of sodium stearyl fumarate and an equal portion of the compacted blend are passed through a 30 mesh screen.

(4) The blends from steps 2 and 3 are layered in a 40 liter BOEHLER blender and blended for 1.5 minutes on medium speed (setting 5).

(5) The resulting blend is compressed with a 11/64" round, deep cup tooling at a target weight of 60 mg and a target hardness of 6 Strong-Cobb Units to yield compressed cores containing 10 mg of omeprazole.

(6) The compressed cores are coated with a mixture of 60% by weight EUGRAGIT L 30D 55 (suspension with 30% solids), 2% by weight polyethylene glycol (PEG 8000) and 38% purified water in a VECTOR COMPULAB coating pan at a spray pump setting of 8-10%.

The resulting enteric coated compressed cores have the following composition:

CORE:

omeprazole	10.00 mg
anhydrous lactose	36.95 mg
microcrystalline cellulose	9.0 mg
sodium lauryl sulfate	1.2 mg
croscarmellose sodium	2.25 mg

ENTERIC COATING:

EUGRAGIT L 30D 55	4.104 mg
polyethylene glycol	0.213 mg

(7) Two enteric coated compressed cores are placed into a capsule shell to yield a capsule dosage form containing 20 mg of omeprazole.

Example 2

This example describes the preparation of lansoprazole 15 and 30 mg capsules having the following composition:


lansoprazole	15 mg
lactose monohydrate	29.8 mg
microcrystalline cellulose	8.5 mg
polysorbate 80	0.6 mg
polyvinylpyrrolidone K-30	1.5 mg
croscarmellose sodium	4 mg
sodium stearyl fumarate	0.6 mg

Preparation:

- (1) Lansoprazole, lactose monohydrate, microcrystalline cellulose, polyvinylpyrrolidone and croscarmellose sodium are sieved through a #40 sieve and mixed dry.
- (2) The powder resulting from step (1) is granulated with water containing polysorbate 80 in a rapid mixer granulator.
- (3) The granulate is passed through an 8 mm sieve, then dried at 40-45°C for 2-3 hours and then passed through a #20 mesh sieve.
- (4) The granules resulting from step (3) are lubricated in a drum mixer - first with croscarmellose sodium and then with sodium stearyl fumarate.
- (5) The lubricated granules are compressed using 4.3 mm round concave punches to a hardness of about 20N-35N at a average weight of 60 mg \pm 2% to yield compressed cores containing 15 mg of lansoprazole.
- (6) The compressed core is coated with a formulation containing EUDRAGIT L30D 55, triethyl citrate and polyethylene glycol 400 in a ratio of 10:1:1 in a 15% aqueous suspension to yield enteric coated compressed cores wherein about 2.4 mg of EUDRAGIT L30D 55 is applied per compressed core.
- (7) A color coat is applied to the enteric coated compressed core to yield a film coat which contains about 1.5 mg of hydroxypropylmethyl cellulose and 1.5 mg of titanium dioxide per core.
- (8) One enteric coated compressed core is placed into a size 3 capsule shell to yield a capsule dosage form containing 15 mg of lansoprazole, or two enteric compressed cores are placed into a size 1 capsule shell to yield a capsule dosage form containing 30 mg of lansoprazole.

We claim:

1. A delayed-release, pharmaceutical capsule dosage form, which comprises one or several enteric-coated, compressed cores encapsulated by a capsule shell, wherein the enteric coated compressed core consists essentially of a mixture of a pharmaceutically acceptable carrier and an pharmaceutically effective amount of a pharmaceutically active compound of the formula (I)



wherein R¹ is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R² is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxy carbonylmethyl or alkylsulfonyl, R³ and R⁵ are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R⁴ is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, or a pharmaceutically acceptable salt thereof;

which mixture has been compressed at a pressure in the range from 350 to 1500 pounds to form a compressed core and the compressed core is directly coated with an effective release-delaying amount of an enteric coating.


2. A capsule dosage form of claim 1 wherein each compressed core has a surface area to volume ratio of from 0.5 to 2.5 mm⁻¹.

3. A capsule dosage form of claim 2 wherein each compressed core has a volume in the range from 13 to 1230 mm³.

4. A capsule dosage form of claim 2 wherein each compressed core has a volume in the range from about 25 mm³ to 450 mm³ and a surface area in the range from about 50 mm² to 350 mm².
5. A capsule dosage form of claim 2 which contains from 1 to 6 compressed cores.
6. A capsule dosage form of claim 3 which contains from 1 to 4 compressed cores.
7. A dosage form of claim 3 wherein the compound of formula (I) is selected from the group consisting of omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole and pantoprazole.
8. A dosage form of claim 5 wherein the compound of formula (I) is selected from the group consisting of omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole and pantoprazole.
9. A dosage form of claim 3 wherein the compound of formula (I) is omeprazole or lansoprazole.
10. A dosage form of claim 3 wherein the compound of formula (I) is omeprazole.
11. A dosage form of claim 7 where the enteric coating is a gastric resistant polymer selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and copolymers, methacrylic acid polymers and copolymers.
12. A dosage form of claim 11 wherein the enteric coating is a copolymer of methacrylic acid and methacrylic acid methyl ester.
13. A dosage form of claim 9 wherein all of the pharmaceutically active compound is contained in 1 or 2 compressed cores.
14. A dosage form of claim 10 wherein all of the pharmaceutically active compound is contained in 1 or 2 compressed cores.

15. A dosage form of claim 9 wherein the bioavailability of the benzimidazole compound is enhanced relative to a pellet- or granule-containing formulation.


16. A method of inhibiting the secretion of gastric acid in a mammalian subject which comprises administering to the subject a delayed-release, pharmaceutical capsule dosage form, which comprises one or more enteric-coated, compressed cores encapsulated by a capsule shell, wherein the enteric-coated compressed core consists essentially of a core which is a mixture of a pharmaceutically acceptable carrier and an effective amount of a pharmaceutically active compound of the formula (I)



wherein R^1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R^2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R^3 and R^5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R^4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4; which mixture has been subjected to compression at a pressure in the range from 500 to 1200 pounds.

17. A method of claim 16 wherein the bioavailability of the benzimidazole compound is enhanced relative to a pellet- or granule-containing formulation.

18. A process for preparing a enteric-coated, capsule dosage form containing a pharmaceutical effective amount of a compound of formula (I)



wherein R^1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R^2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxy carbonylmethyl or alkylsulfonyl, R^3 and R^5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R^4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4;

which consists essentially of the steps of

- (i) compressing a mixture of a compound of formula (I) and a pharmaceutically acceptable carrier at a pressure in the range from 350 to 1500 pounds to form a compressed core which has a surface area to volume ratio of from 0.5 to 2.5 mm^{-1} ;
- (ii) coating the compressed core with an effective release-delaying amount of an enteric coating to form an enteric-coated compressed core; and
- (iii) encapsulating from 1 to 4 enteric-coated compressed cores in a capsule shell to form a delayed-release capsule dosage form containing a pharmaceutically effective amount of a compound of formula (I).

19. A process of claim 18 wherein the pressure is in the range from 500 to 1200 pounds.

20. A process of claim 19 wherein the compound of formula (I) is selected from the group consisting of omeprazole or lansoprazole.

This Page Blank (uspto)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/026210 A3

(51) International Patent Classification⁷: **A61K 31/4439**,
9/28, 9/48, 9/50

(21) International Application Number: **PCT/US01/42298**

(22) International Filing Date:
25 September 2001 (25.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/236,993 29 September 2000 (29.09.2000) -US

(71) Applicant (for all designated States except US): **GENEVA
PHARMACEUTICALS INC.** [US/US]; 2655 West Mid-
way Boulevard, Broomfield, CO 80038 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CULLEN, Dan**
[US/US]; 2385 Cessna Drive, Erie, CO 80516 (US). **PEL-
LONI, Christopher, L.** [US/US]; 2058 Maple Avenue,
Apt. AH1-12, Hatfield, PA 19440 (US).

(74) Agents: **FURMAN, Diane, E.** et al.; Novartis Pharma-
ceuticals Corporation, 564 Morris Avenue, Summit, NJ
07901-1027 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GI, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— with international search report

(88) Date of publication of the international search report:
19 December 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **PROTON PUMP INHIBITOR FORMULATION**

(57) Abstract: Pharmaceutical capsule dosage forms of benzimidazole proton pump inhibitors are prepared by enclosing one or several enteric coated compressed cores in a capsule shell. The inventive formulations are stable and have higher bioavailability of the active ingredient relative to pellet and granule containing formulations.



WO 02/026210 A3

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 01/42298

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/4439 A61K9/28 A61K9/48 A61K9/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 12581 A (PHARMA PASS) 10 April 1997 (1997-04-10) claims examples	1-20
A	EP 0 773 025 A (ESTEVE QUIMICA) 14 May 1997 (1997-05-14) cited in the application claims examples page 2, line 54 page 3, line 21	1-20
A	EP 0 502 556 A (AKTIEBOLAGET HÄSSLE) 9 September 1992 (1992-09-09) claims	1-20
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

16 September 2002

Date of mailing of the international search report

23/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

In 1 Application No

PCT/US 01/42298

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 753 265 A (P.J.A. BERGSTRAND ET AL.) 19 May 1998 (1998-05-19) claims examples -----	1-20

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 01/42298

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 16-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/42298

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9712581	A	10-04-1997	FR 2742050 A1	13-06-1997
			FR 2745181 A1	29-08-1997
			FR 2747573 A1	24-10-1997
			AU 6998796 A	28-04-1997
			AU 713242 B2	25-11-1999
			AU 6998896 A	28-04-1997
			CA 2231223 A1	10-04-1997
			CN 1197456 A	28-10-1998
			CZ 9800879 A3	12-08-1998
			EP 1092434 A1	18-04-2001
			EP 0854718 A2	29-07-1998
			EP 0859612 A2	26-08-1998
			HU 9900467 A2	28-09-1999
			WO 9712580 A2	10-04-1997
			WO 9712581 A2	10-04-1997
			JP 11504343 T	20-04-1999
			JP 3198337 B2	13-08-2001
			JP 10511117 T	27-10-1998
			NO 981284 A	20-03-1998
			NZ 318501 A	29-06-1999
			PL 325838 A1	03-08-1998
			RU 2161481 C2	10-01-2001
			SK 31498 A3	02-12-1998
			US 6207198 B1	27-03-2001
			US 6159499 A	12-12-2000
			US 6248355 B1	19-06-2001
EP 773025	A	14-05-1997	ES 2094694 A1	16-01-1997
			AT 193649 T	15-06-2000
			AU 4540396 A	21-08-1996
			DE 69608767 D1	13-07-2000
			DK 773025 T3	09-10-2000
			EP 0773025 A1	14-05-1997
			ES 2148725 T3	16-10-2000
			FI 963916 A	30-09-1996
			JP 9511257 T	11-11-1997
			SI 773025 T1	31-10-2000
			CA 2184842 A1	08-08-1996
			DE 29623938 U1	05-10-2000
			EP 0993830 A2	19-04-2000
			WO 9623500 A1	08-08-1996
			HU 9603014 A2	30-03-1998
			IL 116673 A	31-10-2000
			PT 773025 T	31-10-2000
			US 5626875 A	06-05-1997
			ZA 9600683 A	30-07-1997
EP 502556	A	09-09-1992	GB 2189699 A	04-11-1987
			AT 84211 T	15-01-1993
			EP 0502556 A1	09-09-1992
			GR 3020501 T3	31-10-1996
			LV 5753 A4	20-12-1996
			AT 139692 T	15-07-1996
			AT 186639 T	15-12-1999
			AU 603568 B2	22-11-1990
			AU 7192287 A	05-11-1987
			CA 1302891 A1	09-06-1992
			CN 87103285 A , B	18-11-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/42298

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 502556	A		CS 8703073 A2	13-06-1989
			DD 260222 B5	09-07-1998
			DE 3751851 D1	01-08-1996
			DE 3751851 T2	31-10-1996
			DE 3783386 D1	18-02-1993
			DE 3783386 T2	06-05-1993
			DE 244380 T1	08-02-1990
			DK 215987 A	31-10-1987
			EG 18517 A	30-04-1993
			EP 0244380 A2	04-11-1987
			EP 0565210 A2	13-10-1993
			ES 2010648 T3	16-07-1994
			ES 2089277 T3	01-10-1996
			ES 2137966 T3	01-01-2000
			FI 871914 A ,B,	31-10-1987
			GR 3032639 T3	30-06-2000
			GR 89300156 T1	12-03-1990
			GR 3007448 T3	30-07-1993
			HK 55497 A	09-05-1997
			HK 104095 A	07-07-1995
			HR 920855 A1	30-06-1995
			HU 44171 A2	29-02-1988
			IE 61837 B	30-11-1994
			JP 1946242 C	10-07-1995
			JP 6067837 B	31-08-1994
			JP 62258316 A	10-11-1987
			KR 9504886 B1	15-05-1995
			LT 2260 R3	15-12-1993
			LV 5393 A3	10-03-1994
			NO 871791 A ,B,	02-11-1987
			NZ 220097 A	26-04-1990
			PH 24440 A	25-06-1990
			PT 84786 A ,B	01-05-1987
			SI 8710680 A ,B	31-12-1996
			SU 1709894 A3	30-01-1992
			US 4853230 A	01-08-1989
			YU 68087 A1	31-08-1988
			ZA 8702379 A	30-12-1987
US 5753265	A	19-05-1998	AU 695971 B2	27-08-1998
			AU 2993895 A	09-02-1996
			BR 9506028 A	14-10-1997
			BR 9506029 A	14-10-1997
			CA 2170644 A1	25-01-1996
			CA 2170995 A1	26-01-1996
			CN 1134667 A	30-10-1996
			CN 1134668 A	30-10-1996
			CZ 9600730 A3	17-07-1996
			EE 3292 B1	16-10-2000
			EP 0723437 A1	31-07-1996
			EP 0724434 A1	07-08-1996
			FI 961058 A	07-03-1996
			FI 961059 A	07-03-1996
			HU 75934 A2	28-05-1997
			JP 9502740 T	18-03-1997
			JP 9502741 T	18-03-1997
			NO 960948 A	07-03-1996
			NO 960949 A	07-03-1996

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/42298

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5753265	A	NZ 289949 A	27-07-1997
		PL 313388 A1	24-06-1996
		PL 313389 A1	24-06-1996
		RU 2166935 C2	20-05-2001
		WO 9601624 A1	25-01-1996
		WO 9601625 A1	25-01-1996
		SK 30096 A3	10-09-1997
		TR 960037 A2	21-06-1996
		TR 960038 A2	21-06-1996
		TW 421599 B	11-02-2001
		ZA 9505546 A	08-01-1996
		ZA 9505547 A	08-01-1996

This Page Blank (uspto)